CCTG Clinical Trials
Public Trial Select
Member Trial Select
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancerClinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment. More >> |
Recently Activated Trials
Member Links
CCTG’s MA.39 trial receives green light from funding bodiesOne of the most promising advances in cancer treatment is the use of biological markers or biomarkers to identify the therapies a particular cancer may or may not respond to. More >> |
Planned Trials
Committees Select
Protecting Cancer Patients from COVID-19
CCTG IC.8 - World-first clinical trial tests a novel immune-boosting strategy
In the race to find new ways to prevent and treat COVID-19, the Canadian Cancer Trials Group (CCTG) has launched an innovative clinical trial focussed on strengthening the immune system for one of the most vulnerable populations – cancer patients.
The trial is called CCTG IC.8: Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure (COV-IMMUNO). IMM-101 is a preparation of safe, heat-killed bacteria that broadly stimulates the innate, or “first-response,” arm of the immune system. Researchers hope that boosting cancer patients’ immune systems with IMM-101 will protect them from developing severe COVID-19 and other dangerous lung infections.
More >>
PR17 (ENZAMET) featured in ASCO's Clinical Cancer Advances 2020
ENZAMET | CCTG PR17 (NCT02446405) study has been highlighted by the American Society of Clinical Oncology (ASCO) 2020 annual report as a major advance in cancer treatment. The results were first presented at ASCO 2019, the trial demonstrated that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone‐sensitive prostate cancer.
More >>
An interview with Senior Investigator Annette Hay
Prof Annette Hay speaks to ecancer at the ASH 2019 meeting in Orlando about accrual barriers and detection of early toxicity signal in older, less-fit patients treated with azacitidine and nivolumab for newly diagnosed acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS). Prof Hay says that AML and MDS are typically diseases of older people, yet these patients are poorly represented in clinical trials.
More >>
Palliative and supportive care presentation at ESMO 2019
Approximately a fifth of patients participating in phase III breast, lung, or colorectal cancer clinical trials conducted by CCTG also used complementary medicines.
More >>
Cell Therapy’s Promise for Canadians Must Include Access
An emerging form of immunotherapy, called adoptive cell transfer, has the potential to transform the way in which cancers are treated.
More >>Planned trials
HD11
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
MA40
Fulvestrant and Ipatasertib for Advanced/Metastatic HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor (FINER)
Recently activated
The rise of precision medicine
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
More >>
TAILORx | MAC12 trial showed no benefit from chemotherapy for many women with breast cancer
Clinical trials are not always about finding a new drug that works but sometimes challenge current standards of care that may help spare patients unnecessary treatment.
More >>
Study results suggest that a new pancreatic cancer treatment regimen should become standard practice world-wide
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
More >>
Canadian Cancer Research Alliance announces award winners
Canadian Cancer Research Alliance has announced the recipients of their 2017 awards: former CCTG Director, Dr. Elizabeth Eisenhauer will recieve the Exceptional Leadership in Cancer Research award and Ms. Judy Needham will receive the Exceptional Leadership in Patient Involvement in Cancer award.
More >>Publications
Clinical trials navigator: Patient-centered access to clinical trials.
J Clin Oncol 38, 2020
Hamm CM;Naccarato K;Sundquist S;Kovacevic S;El-Abed Y;Dancey J;
Role of the total mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) on the development of second primary cancer after complete resection of non-small cell lung cancer (NSCLC).
J Clin Oncol 38, 2020
Gauthier M;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria J;Kratzke RA;Graziano SL;Govindan R;Tsao M;Shepherd FA;
Prognostic and predictive effect of KRAS gene copy number and mutation status in early stage non-small cell lung cancer (NSCLC) patients.
J Clin Oncol 38, 2020
Fung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le Chevalier T;Soria J;Kratzke RA;Graziano SL;Devarakonda S;Govindan R;Tsao M;Shepherd FA;
The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).
J Clin Oncol 38, 2020
Parsons SK;Rodday AM;Scharman C;Andre M;Federico M;Friedberg JW;Friedman DL;Gallamini A;Hay AE;Hoskin P;Johnson P;Kahl BS;Keller FG;Kelly KM;Meyer RM;Radford JA;Raemaekers J;Zinzani PL;Cohen JT;Evens AM;
A cost-utility analysis of apalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).
J Clin Oncol 38, 2020
Parmar A;Timilshina N;Emmenegger U;Alibhai SMH;Smoragiewicz M;Sander B;Chan KK;
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
J Clin Oncol 38, 2020
Hass NB;Puligandla M;Allaf ME;McDermott DF;Drake CG;Signoretti S;Cella D;Gupta RT;Shuch BM;Lara P;Kapoor A;Heng DYC;Leibovich BC;Michaelson MD;Choueiri TK;Jewett MAS;Maskens D;Harshman LC;Master VA;Carducci MA;
Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).
J Clin Oncol 38, 2020
Parsons SK;Bhakta N;Rodday AM;Scharman C;Andre M;Federico M;Friedberg JW;Friedman DL;Gallamini A;Hay AE;Kahl BS;Keller FG;Kelly KM;Meyer RM;Raemaekers J;Robison LL;Hudson MM;Cohen JT;Evens AM;Wong FL;
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trial.
J Clin Oncol 38, 2020
Song AJ;Ding K;Laperriere N;Perry JR;Mason WP;Winch C;O'Callaghan CJ;Menten J;Brandes AA;Phillips C;Fay MF;Nishikawa R;Osoba D;Cairncross G;Roa W;Wick W;Shi W;